Psyence Group Inc. (PSYGF)
USD 0.01
(-33.33%)
USD 0.01
(-33.33%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 3.27 Million CAD | -18.22% |
| 2023 | 4 Million CAD | -8.11% |
| 2022 | 4.35 Million CAD | 3397.44% |
| 2021 | 124.5 Thousand CAD | -11.53% |
| 2020 | 140.73 Thousand CAD | -18.75% |
| 2019 | 173.22 Thousand CAD | 24126.57% |
| 2018 | 715.00 CAD | -10.06% |
| 2017 | 795.00 CAD | 0.0% |
| 2016 | 795.00 CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 FY | 3.27 Million CAD | -18.22% |
| 2024 Q4 | 3.27 Million CAD | 66.78% |
| 2024 Q1 | 2.08 Million CAD | -47.99% |
| 2024 Q3 | 1.96 Million CAD | -10.0% |
| 2024 Q2 | 2.18 Million CAD | 4.75% |
| 2023 Q2 | 2.38 Million CAD | -28.98% |
| 2023 FY | 4 Million CAD | -8.11% |
| 2023 Q4 | 4 Million CAD | 4.75% |
| 2023 Q3 | 3.82 Million CAD | 59.95% |
| 2023 Q1 | 3.36 Million CAD | -22.78% |
| 2022 Q3 | 4.29 Million CAD | -13.02% |
| 2022 FY | 4.35 Million CAD | 3397.44% |
| 2022 Q1 | 5.88 Million CAD | 87393.99% |
| 2022 Q4 | 4.35 Million CAD | 1.48% |
| 2022 Q2 | 4.93 Million CAD | -16.23% |
| 2021 Q2 | 115.65 Thousand CAD | 0.0% |
| 2021 FY | 124.5 Thousand CAD | -11.53% |
| 2021 Q4 | 6730.85 CAD | -94.59% |
| 2021 Q3 | 124.5 Thousand CAD | 7.66% |
| 2020 FY | 140.73 Thousand CAD | -18.75% |
| 2019 FY | 173.22 Thousand CAD | 24126.57% |
| 2018 FY | 715.00 CAD | -10.06% |
| 2017 FY | 795.00 CAD | 0.0% |
| 2016 FY | 795.00 CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AstraZeneca PLC | 100.97 Billion USD | 99.997% |
| Bristol-Myers Squibb Company PFD CONV 2 | 95.15 Billion USD | 99.997% |
| CSPC Pharmaceutical Group Limited | 6.52 Billion USD | 99.95% |
| Clarus Therapeutics Holdings, Inc. | 51.7 Million USD | 93.671% |
| Novartis AG | 99.94 Billion USD | 99.997% |
| PT Kalbe Farma Tbk. | 1.75 Billion USD | 99.814% |